
An international team of researchers led by Dr. Eleanor Fish, Scientist Emeritus at the Toronto General Hospital Research Institute, UHN, and professor in the University of Toronto‘s Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.
According to the new study, published Friday in Frontiers in Immunology, treatment with interferon(IFN)- a2b may significantly accelerate virus clearance and reduce levels of inflammatory proteins in COVID-19 patients.
The research team found that treatment with this drug, which has been used clinically for many years, significantly reduced the duration of detectable virus in the upper respiratory tract, on average by about seven days. It also reduced blood levels of interleukin(IL)-6 and C-reactive protein (CRP), two inflammatory proteins found in COVID-19 patients.
Dr. Fish says the research team considered IFN-a therapy for COVID-19 after they demonstrated interferon provided therapeutic benefit during the SARS outbreak of 2002 and 2003.
“Rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the ‘first responders’ in terms of treatment,” says Dr. Fish.
“Interferons have been approved for clinical use for many years, so the strategy would be to ‘repurpose’ them for severe acute virus infections.”
Boosting a natural defence mechanism
Interferons are a group of signaling proteins released by the human body in response to all viruses. As Dr. Fish explains, they are a “first line of defence.”
They target different stages of a virus’s life cycle, inhibiting them from multiplying. They also boost an immune response by activating different immune cells to clear an infection. Some viruses, however, can block this natural defense mechanism.
“But it is possible to override this block. If a virus blocks interferon production, then treating with interferon can offset this.”
Study details
The researchers conducted this exploratory study on a group of 77 patients with COVID-19 in Wuhan, China. These patients were admitted to Union Hospital, Tongii Medical College, between January 16 and February 20, 2020. They represented moderate cases of the disease as none of the patients required intensive care or prolonged oxygen supplementation or intubation.
Despite the study’s limitations of a small, non-randomized group of patients, the work provides several important and novel insights into COVID-19 disease, notably that treatment with IFN-a2b can accelerate viral clearance from the upper respiratory tract and also reduce circulating levels of inflammatory factors that are associated with severe COVID-19.
Dr. Fish says a randomized clinical trial is a crucial next step. According to her, a clinical trial with a larger group of infected patients who are randomized to treatment or placebo would further this research.
In the meantime, the findings from this study are the first to suggest therapeutic efficacy of IFN-a2b as an available antiviral intervention for COVID-19, which may also benefit public health measures by shortening the duration of viral clearance and therefore slowing the tide of the pandemic.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Recovery of COVID-19 patients
- 'What I want are recovery narratives': CBC Radio host Gill Deacon on life with long COVID
"It can be a challenge to stay present, to not grieve what I have lost or bemoan what has befallen me. I take it, as the banal but truthful platitude goes, one day at a time," writes CBC Radio Here & ...
- Covid-19: another 454 patients recover in Sri Lanka
The Health Ministry reported that another 454 coronavirus patients have completed their recovery and have been discharged within the last 24 hours. This brings the tally number of Covid-19 recoveries ...
- Nutraceuticals for The Recovery of COVID-19 Patients
The COVID-19 pandemic continues to have a tremendous impact on health in 2021; and continues to affect many lives, living conditions and society in almost every country on this planet. Since early ...
- Why aren't kids going to school? COVID taught them some bad habits.
Chronic absenteeism is part of a larger education crisis that puts students' futures and the nation's economy at risk.
- COVID-19: The Road to Recovery
Canada is early in its rollout of COVID-19 vaccines, and unknowns remain around the legality of an employer’s role in supporting vaccination efforts. In most cases, employers will be legally limited ...
Go deeper with Google Headlines on:
Recovery of COVID-19 patients
[google_news title=”” keyword=”recovery of COVID-19 patients” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antiviral drug
- Pfizer: Disastrous 2023 Hits New Low With Weight Loss Drug Failure
Using its COVID vaccine and antiviral cash windfall, since 2021 Pfizer has been on a major M&A spending spree. Since mid-2021 Pfizer has completed: a $2.3bn deal for Trillium Therapeutics and its 2 CD ...
- COVID wave: What's the latest on antiviral drugs, and who is eligible in Australia?
Australia is experiencing a fresh wave of COVID, seeing increasing cases, more hospitalizations and a greater number of prescriptions for COVID antivirals dispensed over recent months.
- The perpetual challenge of Antiviral drug-resistance
We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the ...
- Emerging and Old Viral Diseases: Antiviral Drug Discovery from Medicinal Plants, Volume II
This Research Topic is part of a series. See also Volume I: Emerging and Old Viral Diseases: Antiviral Drug Discovery from Medicinal Plants. In ...
- COVID wave: what’s the latest on antiviral drugs, and who is eligible in Australia?
We now have two drugs called Paxlovid and Lagevrio that treat the virus itself. But are these drugs effective against current variants? And who is eligible to receive them? Here’s what to know ...
Go deeper with Google Headlines on:
Antiviral drug
[google_news title=”” keyword=”antiviral drug” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]